Last updated 2026-07-22
- Raised $1.9M Undisclosed Round led by Peregrine Ventures, May 2022
Total raised
$1.9M
Last: Undisclosed Round 2022-06
Stage
Seed
Founded
2017
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Levation Pharma is an Israeli-American pharmaceutical company focused on developing new therapeutics for ophthalmology and aesthetic medicine. The company's lead product, LEV102, is a proprietary aqueous gel containing oxymetazoline, designed for the transdermal treatment of acquired blepharoptosis (droopy upper eyelids). LEV102 is intended to be applied topically to the upper eyelids to stimulate Mueller's muscle, causing the eyelid to lift. The company was founded on intellectual property licensed from its founders and is backed by venture capital firms Pontifax and Peregrine Ventures. Levation Pharma operates out of Los Angeles.
Funding history · 1 round · $1.9M total
2022-05
Undisclosed Round
$1.9M
★ Peregrine VenturesPontifax
Headcount over time
From 6 (2021-07) to 2 (2025-01) · -4 (-67%) · 2 points · source: Finder history + radar grounding
Q&A
- What is Levation Pharma's primary focus?
- Levation Pharma is an Israeli-American company focused on the treatment of Acquired Blepharoptosis, a condition where upper eyelids droop, often due to the natural aging process.
- What product has Levation Pharma developed?
- Levation Pharma has developed LEV-102, a proprietary odorless, colorless, rapidly drying aqueous gel designed to be applied to the upper eyelids. It functions as an eyeshadow primer and contains oxymetazoline as its active pharmaceutical ingredient.
- How does LEV-102 work to treat droopy eyelids?
- LEV-102 is designed to allow oxymetazoline to penetrate the upper lid and reach Mueller’s muscle, triggering a slight contraction that lifts the upper lid.
- When was Levation Pharma founded?
- Levation Pharma was founded in September 2017.
- What is Levation Pharma's current employee count?
- Levation Pharma has 1-10 employees.
- What is the total funding Levation Pharma has raised to date?
- Levation Pharma has raised a total of $1,930,000.
- When was Levation Pharma's last funding round and who were the lead investors?
- Levation Pharma's last funding round was in June 2022, with Peregrine Ventures and Pontifax as investors.
- In which sector does Levation Pharma primarily operate?
- Levation Pharma operates primarily in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Team · 1
Houman Hemmati
Founder · Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsCosmetics
Business model
B2B
Highlights
1 Patents
Tags
drug-discoveryeye-diseasespharmaceuticalstopical-treatmentophthalmology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | levationpharma.com/ |
|---|---|
| linkedin.com/company/90570479 |
Identifiers & details
| Legal name | Levation Pharma Ltd. |
|---|---|
| Founded | 2017-11 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | levationpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515723658 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-09-19 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 6 — violation (1), annual_report (1), people (2), other (1), shares_capital (1) |
| Registered address | החרש 20 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-22 | עדכון הפרה |
| 2026-06-22 | דו~ח שנתי-הקצאת מניות |
| 2026-07-12 | עדכון דירקטורים-הסרת דירקטור |
| 2026-07-12 | עדכון דירקטורים-הוספת דירקטור |
| 2025-11-04 | שינוי בתקנון |
| 2025-11-03 | שינוי בהרכב הון - מניות-הפחתת הון רשום |